Serum Institute of India Limited ' Product Pipeline Review ' 2012

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Serum Institute of India Limited ' Product Pipeline Review ' 2012
Published on December 2012

Report Summary


Summary

Global Market Direct's pharmaceuticals report, "Serum Institute of India Limited - Product Pipeline Review - 2012" provides data on
the Serum Institute of India Limited's research and development focus. The report includes information on current developmental
pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Serum Institute of India
Limited's corporate website, SEC filings, investor presentations and featured press releases, both from Serum Institute of India
Limited and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Serum Institute of India Limited - Brief Serum Institute of India Limited overview including business description, key information and
facts, and its locations and subsidiaries.
- Review of current pipeline of Serum Institute of India Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities,
across the globe.
- Product profiles for late stage and clinical stage products of Serum Institute of India Limited with complete description of the
product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Serum Institute of India Limited's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Serum Institute of India Limited's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Serum Institute of India Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Serum Institute of India Limited's R&D portfolio and develop key strategic
initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Serum Institute of India Limited.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Serum Institute of India Limited and identify potential opportunities in those areas.

Serum Institute of India Limited ' Product Pipeline Review ' 2012 (From Slideshare) Page 1/6


Table of Content

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Serum Institute of India Limited Snapshot 5
Serum Institute of India Limited Overview 5
Key Information 5
Key Facts 5
Serum Institute of India Limited ' Research and Development Overview 6
Key Therapeutic Areas 6
Serum Institute of India Limited ' Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products ' Monotherapy 9
Pipeline Products ' Combination Treatment Modalities 10
Serum Institute of India Limited ' Pipeline Products Glance 11
Serum Institute of India Limited ' Late Stage Pipeline 11
Phase III Products/Combination Treatment Modalities 11
Serum Institute of India Limited Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Serum Institute of India Limited ' Drug Profiles 14
Measles Vaccine 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Meningococcal A Conjugate Vaccine + EPI Vaccines 15
R&D Progress 15
PsA-TT 17
R&D Progress 17
Purified Vero Cell Rabies Vaccine 19
R&D Progress 19
Serum Institute of India Limited ' Pipeline Products by Route of Administration 20
Serum Institute of India Limited ' Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Financial Deals Landscape 23
Serum Institute of India Limited, Deals Summary 23



Serum Institute of India Limited, Pharmaceuticals & Healthcare, Deal Details 25
Asset Transactions 25
Serum Institute of India Acquires Production Facilities Of Netherlands Vaccine Institute For $40 Million 25
Partnerships 27
Merck Enters Into Co-Development Agreement With Serum Institute of India 27
VaxyGen Vaccines Enters Into Collaboration With Serum Institute Of India 29
Akorn Enters Into An Agreement With Serum Institute Of India 30
Akorn Enters Into Distribution Agreement With Serum Institute Of India 31
Lipoxen Enters Into Co-Development Agreement With Serum Institute 32
Lyka Labs Enters Into Co-Development Agreement With Serum Institute 34
Licensing Agreements 35
BioDiem Enters Into Licensing Agreement With Serum Institute Of India 35
Serum Institute of India Enters Into Licensing Agreement With Dowpharma 36
Health Protection Agency Enters Into Licensing Agreement With Serum Institute 37
Equity Offering 38
Akorn Completes Private Placement Of $2.5 Million 38
Lipoxen Completes Private Placement Of $4.6 Million 40
Akorn Completes Private Placement Of $7.01 Million With Serum 42
Acquisition 46
Serum Institute Of India Acquires Bilthoven Biologicals, Monoclonal Antibodies And Vaccine Maker, For $101 Million 46
Serum Institute Acquires 5% Stake In Lyka Labs 48
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51

List of Tables

Serum Institute of India Limited, Key Information 5
Serum Institute of India Limited, Key Facts 5
Serum Institute of India Limited ' Pipeline by Indication, 2012 7
Serum Institute of India Limited ' Pipeline by Stage of Development, 2012 8
Serum Institute of India Limited ' Monotherapy Products in Pipeline, 2012 9
Serum Institute of India Limited ' Combination Treatment Modalities in Pipeline, 2012 10
Serum Institute of India Limited ' Phase III, 2012 11
Serum Institute of India Limited ' Phase II, 2012 12
Serum Institute of India Limited ' Phase I, 2012 13
Serum Institute of India Limited ' Pipeline By Route of Administration, 2012 20
Serum Institute of India Limited, Other Locations 21
Serum Institute of India Limited, Deals Summary 23
Serum Institute of India Acquires Production Facilities Of Netherlands Vaccine Institute For $40 Million 25



Merck Enters Into Co-Development Agreement With Serum Institute of India 27
VaxyGen Vaccines Enters Into Collaboration With Serum Institute Of India 29
Akorn Enters Into An Agreement With Serum Institute Of India 30
Akorn Enters Into Distribution Agreement With Serum Institute Of India 31
Lipoxen Enters Into Co-Development Agreement With Serum Institute 32
Lyka Labs Enters Into Co-Development Agreement With Serum Institute 34
BioDiem Enters Into Licensing Agreement With Serum Institute Of India 35
Serum Institute of India Enters Into Licensing Agreement With Dowpharma 36
Health Protection Agency Enters Into Licensing Agreement With Serum Institute 37
Lipoxen Completes Private Placement Of $4.6 Million 40
Akorn Completes Private Placement Of $7.01 Million With Serum 42
Serum Institute Of India Acquires Bilthoven Biologicals, Monoclonal Antibodies And Vaccine Maker, For $101 Million 46
Serum Institute Acquires 5% Stake In Lyka Labs 48

List of Figures

Serum Institute of India Limited ' Pipeline by Indication, 2012 7
Serum Institute of India Limited ' Pipeline by Stage of Development, 2012 8
Serum Institute of India Limited ' Monotherapy Products in Pipeline, 2012 9
Serum Institute of India Limited ' Combination Treatment Modalities in Pipeline, 2012 10
Serum Institute of India Limited ' Pipeline By Route of Administration, 2012 20


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 1 500.00 Quantity: _____

Site License--USD 3 000.00 Quantity: _____

Corporate License--USD 4 500.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Serum Institute of India Limited ' Product Pipeline Review ' 2012

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

Serum Institute of India Limited ' Product Pipeline Review ' 2012